Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
QTTB 
Q32 Bio Inc (QTTB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: QTTB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 163.12% | Avg. Invested days 69 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 20.86M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 1.34 - 53.79 | Updated Date 08/30/2025 |
52 Weeks Range 1.34 - 53.79 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.34 |
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.8 | Actual -0.78 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.95% | Return on Equity (TTM) -491.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -15277079 | Price to Sales(TTM) - |
Enterprise Value -15277079 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 12197600 | Shares Floating 5426353 |
Shares Outstanding 12197600 | Shares Floating 5426353 | ||
Percent Insiders 6.57 | Percent Institutions 69.51 |
Upturn AI SWOT
Q32 Bio Inc
Company Overview
History and Background
Q32 Bio Inc. is a clinical stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Details of its founding year and specific milestones are not publicly available.
Core Business Areas
- ADAPTix Platform: Q32 Bio Inc.'s proprietary ADAPTix platform is designed to discover and develop novel biologics that target the bodyu2019s innate immune system to restore immune homeostasis.
- Bemdanekimab: Bemdanekimab (formerly known as Q32-001) is a fully human anti-IL-7Ru03b1 antibody being developed for the treatment of autoimmune diseases.
Leadership and Structure
Details regarding the complete leadership team and organizational structure of Q32 Bio Inc. are limited in readily available public sources.
Top Products and Market Share
Key Offerings
- Bemdanekimab: Bemdanekimab is Q32 Bio Inc's lead product candidate. As a clinical-stage asset, it currently generates no revenue. It is targeting autoimmune diseases. Competitors include companies developing therapies in the same disease areas, such as those targeting IL-23, IL-17, and TNF-alpha.
Market Dynamics
Industry Overview
The autoimmune disease therapeutics market is experiencing significant growth, driven by an increasing prevalence of autoimmune disorders and advancements in treatment options.
Positioning
Q32 Bio Inc. is positioned as a clinical-stage biotechnology company focused on developing novel therapies targeting the innate immune system. Its competitive advantage lies in its ADAPTix platform and the potential of Bemdanekimab.
Total Addressable Market (TAM)
The TAM for autoimmune disease therapeutics is substantial and expected to grow significantly in the coming years. Q32 Bio Inc. is positioned to capture a portion of this market with successful development and commercialization of its pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary ADAPTix platform
- Novel approach targeting the innate immune system
- Clinical-stage asset (Bemdanekimab)
- Experienced management team
Weaknesses
- Limited financial resources as a clinical stage company
- Dependence on the success of Bemdanekimab
- High risk associated with drug development
- Lack of marketed products
Opportunities
- Positive clinical trial results for Bemdanekimab
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through the ADAPTix platform
- Increasing prevalence of autoimmune diseases
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- JNJ
- BMY
- MRK
Competitive Landscape
Q32 Bio Inc. faces intense competition from established pharmaceutical companies with greater resources and marketed products. Its advantage lies in its novel approach and potentially differentiated therapies.
Growth Trajectory and Initiatives
Historical Growth: As a clinical-stage company, historical growth is primarily measured by progress in clinical development.
Future Projections: Future growth depends on the successful development and commercialization of Bemdanekimab and other pipeline candidates. Analyst estimates are not readily available.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Bemdanekimab and continued development of the ADAPTix platform.
Summary
Q32 Bio Inc. is a clinical-stage biotechnology company with a promising platform and lead asset targeting autoimmune diseases. Its strength lies in its innovative approach, but its weaknesses include limited resources and dependence on clinical trial success. The company needs to successfully navigate clinical trials and secure partnerships to capitalize on the growing autoimmune disease market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Q32 Bio Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2018-03-28 | CEO & Director Ms. Jodie Pope Morrison | ||
Sector Healthcare | Industry Biotechnology | Full time employees 27 | Website https://www.q32bio.com |
Full time employees 27 | Website https://www.q32bio.com | ||
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.